Adial Pharmaceuticals, Inc. (ADIL)
3.92
-0.30
(-7.11%)
USD |
NASDAQ |
Oct 23, 16:00
4.05
+0.13
(+3.32%)
After-Hours: 20:00
Adial Pharmaceuticals Enterprise Value : 43.93M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 43.93M |
| October 22, 2026 | 44.71M |
| October 21, 2026 | 44.43M |
| October 20, 2026 | 43.66M |
| October 19, 2026 | 43.14M |
| October 16, 2026 | 42.80M |
| October 15, 2026 | 41.88M |
| October 14, 2026 | 41.51M |
| October 13, 2026 | 42.27M |
| October 12, 2026 | 42.82M |
| October 09, 2026 | 43.87M |
| October 08, 2026 | 44.06M |
| October 07, 2026 | 44.11M |
| October 06, 2026 | 44.08M |
| October 05, 2026 | 45.06M |
| October 02, 2026 | 44.45M |
| October 01, 2026 | 44.48M |
| September 30, 2026 | 44.16M |
| September 29, 2026 | 44.53M |
| September 28, 2026 | 44.24M |
| September 25, 2026 | 44.71M |
| September 24, 2026 | 45.29M |
| September 23, 2026 | 44.24M |
| September 22, 2026 | 44.66M |
| September 21, 2026 | 45.19M |
| Date | Value |
|---|---|
| September 18, 2026 | 46.39M |
| September 17, 2026 | 47.31M |
| September 16, 2026 | 47.39M |
| September 15, 2026 | 46.76M |
| September 14, 2026 | 46.76M |
| September 11, 2026 | 46.50M |
| September 10, 2026 | 49.38M |
| September 09, 2026 | 49.20M |
| September 08, 2026 | 51.10M |
| September 04, 2026 | 52.33M |
| September 03, 2026 | 51.12M |
| September 02, 2026 | 50.23M |
| September 01, 2026 | 49.26M |
| August 31, 2026 | 48.73M |
| August 28, 2026 | 48.34M |
| August 27, 2026 | 48.57M |
| August 26, 2026 | 49.23M |
| August 25, 2026 | 48.92M |
| August 24, 2026 | 47.81M |
| August 21, 2026 | 49.95M |
| August 20, 2026 | 49.13M |
| August 19, 2026 | 48.75M |
| August 18, 2026 | 47.94M |
| August 17, 2026 | 46.74M |
| August 14, 2026 | 44.08M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.903B |
| Corcept Therapeutics, Inc. | 8.967B |
| Veru, Inc. | 15.08M |
| Johnson & Johnson | 662.44B |
| Eli Lilly & Co. | 1.245T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -51.99M |
| Total Expenses (Quarterly) | 51.99M |
| EPS Diluted (Quarterly) | -11.25 |
| Earnings Yield | -422.0% |
| Normalized Earnings Yield | -252.20 |